Nanomedicines for the Treatment of Trypanosomiasis

Abstract

Trypanosomiasis is a neglected tropical disease that is mainly prevalent in low- and middle-income countries including regions of Africa, Asia, and America. Except for fexinidazole which was discovered in late 2018, no new drug has been discovered in the last 50 years for the treatment of trypanosomiasis. Furthermore, emergence of drug resistance against FDA-approved antitrypanosomal drugs has also significantly affected the therapy. Nanotechnological interventions of the existing drugs have shown significant improvement in the therapeutic potential of FDA-approved drugs in preclinical research. The chapter focuses on the nanomedicines-based treatment of trypanosomiasis. A brief discussion on vaccine delivery against trypanosome has also been included.